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Objective: to estimate the prevalence of serological markers for hepatitis B and C in patients with 
diabetes mellitus and analyze potential associated factors. Method: a cross-sectional study with 
255 patients with diabetes mellitus. Demographic, clinical, and risk behavior factors for hepatitis 
B and C were selected. The markers HBsAg, Anti-HBc IgG, Anti-HBc IgM, Anti-HBs, and Anti-HCV 
were investigated. A questionnaire and venous blood collection and inferential statistical analysis 
were used. Results: 16.8% of the patients had a total reactive Anti-HBc marker, 8.2% an isolated 
Anti-HBs, and 75% were non-reactive for all hepatitis B markers. No case of reactive HBsAg was 
found and 3.3% of the patients had a reactive anti-HCV marker. The prevalence of prior hepatitis 
B virus infection was directly associated with the time of diabetes mellitus and the prevalence 
of hepatitis C virus infection was not associated with the investigated variables. The prevalence 
of hepatitis B and C infection in patients with diabetes mellitus was higher when compared to 
the national, with values of 16.8% and 3.3%, respectively. Conclusion: the results suggest that 
patients with diabetes are a population of higher vulnerability to hepatitis B and C, leading to the 
adoption of preventive measures of their occurrence.
Descriptors: Diabetes Mellitus; Hepatitis B; Hepatitis C; Immunization Coverage; Liver Diseases; 
Nursing. 
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Introduction
The international literature shows outbreaks of 
hepatitis B virus (HBV) and hepatitis C virus (HCV) infection 
in the hospital, outpatient, and long-term care facilities. 
Infection cases have been shown to be more frequent 
in patients with diabetes mellitus (DM) than in those 
without the disease, suggesting that patients with DM are 
potentially more susceptible to HBV and HCV infection as a 
result of treatment and control procedures of the disease, 
in particular, the monitoring of capillary glycemia(1-8).
These outbreaks occur when infection control 
standards during capillary glycemia monitoring are 
neglected, such as the sharing of lancet pens, lancets, 
and glucometers without the proper disinfection process 
due to the transmission of microorganisms through the 
blood. HBV and HCV can survive on surfaces such as lancet 
pens, lancets, and glucometers on average for five to 
seven days, even in the absence of visible blood. During 
this period, the virus can cause infection if it reaches the 
bloodstream of a susceptible person(9-10).
There is evidence that the severity and lethality 
related to HBV and HCV infection are higher in patients 
with DM than in those without the disease. Studies show 
that in patients infected with HBV and HCV, the presence 
of DM can accelerate the progression of liver disease, lead 
to cirrhosis, hepatocellular carcinoma, and death(11-12). In 
addition, HBV and HCV infection may negatively influence 
the glycemic control of patients with DM, increasing the 
risk of hyperglycemia(13-15).
However, in Brazil, there is a shortage of studies 
regarding the behavior of hepatitis B and C in patients with 
DM. Regarding hepatitis C, four studies were identified 
in patients with DM(16-18). One of them showed a high 
prevalence of hepatitis C in patients with type 2 diabetes 
mellitus (DM2) when compared to blood donors without 
DM(16). Another study also found a high prevalence of 
hepatitis C in patients with DM2(18). On the other hand, 
studies did not identify a difference in the prevalence of 
hepatitis C in patients with and without DM(14) and cases 
of hepatitis C in investigated patients with DM2(17).
A study on the occurrence of hepatitis showed the 
magnitude of the prevalence of Hepatitis A, B, and C Virus 
Infections in the Brazilian macro-regions and represented 
a major step in coping with hepatitis in Brazil(19). However, 
the behavior of the disease in individuals with DM and risk 
factors related to infection in this population is unknown.
Thus, considering the significant increase in the 
prevalence of DM in the city of Ribeirão Preto, SP, Brazil, 
from 12.1% in 1997 to 15.1% in 2006, the impact of HBV 
and HCV infection on morbidity and mortality, aggravated 
by DM, that patients with DM constitute an increased 
risk population for hepatitis B and C, this study aimed to 
estimate the prevalence of serological markers for hepatitis 
B and C in patients with DM and analyze potential related 
risk factors. We believe that the proposed study can provide 
subsidies to know the magnitude of the problem and to 
advance the production of knowledge about hepatitis B 
and C and DM. This study may represent the emergence 
of a new research topic that could lead to other studies, 
translating into the quality of health information and, 
therefore, an improvement in the healthcare network.
Method
This is a cross-sectional study carried out in a secondary 
health unit in of a city in the State of São Paulo, Brazil. The 
study population consisted of 314 patients with type 1 and 
2 DM, who attended at least one consultation in the period 
from July to December 2014. All patients of both sexes, 
aged 18 years or more, with a diagnosis of type 1 and 2 
DM registered in the health records, and who attended the 
medical consultation from July to December 2014 were 
considered as eligible. Seven patients were excluded due to 
hearing or cognitive limitations that made it impossible to 
answer the questions of the instrument, and other 17 due 
to the difficulty of establishing contact by the researcher. 
Thus, 290 patients with DM were invited to participate in the 
study, of whom 35 refused. The main reasons cited for the 
refusal were the lack of time to answer the questionnaire, 
lack of interest in participating in the study because they 
had already participated in other research projects, and 
unavailability for blood collection. The convenience sample 
consisted of 255 patients with DM who attended the medical 
consultation during the data collection period and met the 
inclusion criteria. This value (n=255) represents 88% of the 
patients invited to participate in the study, 81% of the study 
population and 39% of the patients with DM attended in that 
unit in 2014. The explanatory variables were demographic 
(sex, age, and schooling) and clinical (DM time, insulin use, 
capillary glycemia monitoring, medical, surgical, diagnostic, 
and therapeutic interventions, behaviors and situations of 
risk for hepatitis B and C), and the outcomes were HBV 
and HCV infection.
For this study, the researcher elaborated the 
questionnaire Occurrence of Serological Markers for 
Hepatitis B and C in Patients with Diabetes Mellitus based 
on the questionnaire for adolescents and adults used in the 
National Survey of Prevalence of Hepatitis A, B and C Virus 
Infections(20), the researcher’s experience with patients with 
DM, and an extensive literature review on the subject(7-8,19-23). 
The questionnaire was composed of 96 questions subdivided 
into five parts: Identification (11 questions); Demographic 
variables (four questions); Clinical variables (51 questions); 
Behavioral variables (24 questions); and Results of serology 
tests for hepatitis B and C (six questions).
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The data collection instrument was pre-tested with 
ten patients in order to identify possible adjustments in the 
sequence of questions, test the approach to the patient, as 
well as estimate the time of application of the questionnaire. 
For data collection, the researcher had the collaboration of 
a student of Scientific Initiation previously qualified in order 
to standardize it. After the application of the pre-test, the 
questionnaire was maintained with no need for adjustments 
regarding its form and content. The ten patients were 
included in the final study sample. The data collection was 
carried out from July to December 2014.
Among the 255 patients, 226 attended the unit to 
collect blood, 19 performed the collection at home, and 
10 patients refused to collect blood. Thus, 245 patients 
performed blood collection. The main reasons for the 
refusal were the lack of time and the withdrawal from 
participation in this phase of data collection.
The statistical analysis of the data was performed using 
the program STATA 11.0 (StataCorp LP, College Station, 
USA). The description of demographic and clinical data 
was presented through descriptive statistics, considering 
all the patients who participated in the study (n=255). The 
serological analysis for hepatitis B in patients who underwent 
blood sampling (n=245) enabled to evaluate the presence of 
the markers HBsAg, Anti-HBc IgG, Anti-HBc IgM, e Anti-HBs. 
Because the markers HBsAg and Anti-HBc IgM were non-
reactive for all patients for analysis and data presentation, 
the marker total Anti-HBc was considered as equivalent 
to Anti-HBc IgG. The serological analysis for hepatitis C 
allowed evaluating the presence of the marker Anti-HCV. 
A reactive result for this marker was considered an HCV 
infection. The univariate analysis of possible associations 
between demographic and clinical variables and HBV and 
HCV infection was determined by the Pearson-corrected 
chi-square test or two-tailed Fisher exact test and Wilcoxon 
test. The project was approved by the Research Ethics 
Committee under No. CAAE 24638213.2.0000.5393.
Results
The demographic and clinical characteristics of the 
255 (100%) investigated patients are described in Table 1.
Among the 245 (100%) patients who attended 
the blood collection, 41 (16.8%) presented a marker 
corresponding to prior infection with a spontaneous cure, 
20 (8.2%) presented vaccination seroconversion and, 184 
(75%) presented susceptibility to infection. No cases of acute 
or chronic hepatitis B were found. Therefore, the prevalence 
of prior HBV infection found in patients with DM was 16.8%.
Table 2 shows the results obtained from the univariate 
analysis of prior HBV infection according to demographic and 
clinical variables. The prior infection had a direct association 
with age (p=0.014) and DM time (p=0.043). No significant 
association was observed for the other variables.
Table 3 shows the univariate analysis of prior infection 
according to variables related to the history of medical, 
surgical, diagnostic, and therapeutic interventions and 
situations and behaviors of risk for hepatitis B. The results 
show an association between prior infection and report of 
home contact with case of hepatitis B (p=0.001), work as 
a police officer (p=0.016), and higher number of sexual 
partners throughout life (p=0.004).
The explanatory variables included in the logistic 
regression analysis were those that showed a possible 
association with the outcome (p≤0.20). Among the 
variables included in the model, disease duration remained 
directly associated with the prior infection after the 
multivariate analysis, in which the DM time increases 
the risk of hepatitis B in approximately 4% each year of 
diagnosis of the disease. In addition, the work as a police 
officer was associated with infection (Table 4).
Among the 245 investigated patients, 8 (3.3%) 
presented a reactive anti-HCV marker. Therefore, the 
prevalence of HCV infection found in patients with DM 
was 3.3%. No significant association was found between 
the investigated demographic and clinical variables and 
HCV infection.
Table 1 – Distribution of patients with DM* according to 
demographic and clinical variables. Ribeirão Preto, SP, 
Brazil, 2014





Median (p25-p75) 63 (55-71)
Schooling
Illiterate 9 3.5
Adult literacy 2 0.8
Incomplete 1st to 4th grade of Elementary School 51 20.0
Complete 1st to 4th grade of Elementary School 69 27.1
Incomplete 5th to 8th grade of Elementary School 26 10.2
Complete 5th to 8th grade of Elementary School 31 12.2
Incomplete High School 8 3.1
Complete High School 39 15.3
Incomplete Higher Education 10 3.9
Complete Higher Education 10 3.9
Time of DM* (years)




Monitoring of capillary glycemia
No 65 25.5
Yes 190 74.5
*DM – Diabetes mellitus
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Table 2 – Distribution of patients with DM* with and without 
prior hepatitis B according to demographic and clinical 
variables of DM*. Ribeirão Preto, SP, Brazil, 2014
Variables
Total Anti-HBc†
p (-)  (+)
n % n %
Total 204 83.2 41 16.8
Gender
Male 63 30.9 17 41.5
Female 141 69.1 24 58.5 0.187‡
Age
Median (p25-p75) 62.8 (55.2-69.3) 68.4 (58.9-75.2) 0.014§
Schooling
Illiterate 6 2.9 3 7.3
Adult literacy 1 0.5 1 2.4
Incomplete 1st to 4th 
grade of Elementary 
School
40 19.6 9 22.0
Complete 1st to 4th 
grade of Elementary 
School
57 28.0 8 19.5
Incomplete 5th to 8th 
grade of Elementary 
School
19 9.3 6 14.6
Complete 5th to 8th 
grade of Elementary 
School
25 12.3 4 9.8
Incomplete High 
School 8 3.9 - -
Complete High 
School 31 15.2 7 17.1
Incomplete Higher 
Education 8 3.9 2 4.9
Complete Higher 
Education 9 4.4 1 2.4 0.521
II
Time of DM* (years)
Median (p25-p75) 10 (4-19) 12 (10-23) 0.043II
Use of insulin
No 82 40.2 19 46.3
Yes 122 59.8 22 53.7 0.466‡
Monitoring of capillary glycemia
No 51 25.0 10 24.4
Yes 153 75.0 31 75.6 0.934‡
*DM – Diabetes mellitus; †Anti-HBc – Antibody (IgM or IgG) against 
hepatitis B virus core antigen; ‡Pearson-corrected chi-square test; 
§Wilcoxon test; ||Two-tailed Fisher exact test
Table 3 – Distribution of patients with DM* with and without 
prior hepatitis B according to the history of medical, 
surgical, diagnostic, and therapeutic interventions and 
situations and behaviors of risk for hepatitis B. Ribeirão 
Preto, SP, Brazil, 2014
Variables
Total Anti-HBc†
p (-)  (+)
n % n %
Total 204 83.2 41 16.8
History of interventions‡
Hospitalization 132 64.7 27 65.8 0.888§
Surgery 161 16.3 33 80.5 0.822§
Blood/derivative transfusion 40 19.6 4 9.8 0.181II
Dental treatment 162 79.4 29 70.7 0.221§
Endoscopy 75 36.8 14 34.2 0.750§
Hemodialysis 3 1.5 - - 1.000II
Situations and behaviors of risk‡
Home contact with case of 
hepatitis B 3 1.5 6 14.6 0.001
II
Sexual contact with case of 
hepatitis B 1 0.5 - - 1.000
II
Sharing of sharps 84 41.2 13 31.7 0.258II
Tattoo 8 3.9 1 2.4 1.000II
Piercing 4 2.0 - - 1.000II
Health professional 19 9.3 4 9.8 1.000II
Work as a police officer 1 0.5 3 7.3 0.016‡
Work as a penitentiary 
agent/prison officer
1 0.5 - - 1.000II
Worker collecting 
household/hospital waste 7 3.4 1 2.4 1.000
II
Work as a manicurist/
chiropodist/podiatrist 11 5.4 1 2.4 0.696
II
Smoked drugs 3 1.5 1 2.4 0.522II
Smelled drugs 2 1.0 1 2.4 0.424II
Condom use 16 7.8 2 4.9 1.000II
Sexually transmitted 
disease 30 14.7 8 19.5 0.438
II
Number of sexual partners 
throughout life
Median (p25-p75)
1 (1-3.5) 3 (1-10) 0.004¶
Frequency of alcohol consumption (last three months)
None 153 75.0 29 70.7
Once a month 19 9.3 4 9.8
Two to three times a month 15 7.4 3 7.3
One to two days a week 13 6.4 2 4.9
Three to four days a week 1 0.5 3 7.3
Almost everyday 2 1.0 - -
Every day 1 0.5 - - 0.202‡
*DM – Diabetes mellitus; †Anti-HBc – Antibody (IgM or IgG) against 
hepatitis B virus core antigen; ‡Non-mutually exclusive categories; 
§Pearson-corrected chi-square test; ||Two-tailed Fisher exact test; 
¶Wilcoxon test
Table 4 − Logistic regression model for prior hepatitis B. Ribeirão Preto, SP, Brazil, 2014
Variables*  OR† (95% CI‡)  p Standard error
Female 0.74 (0.32-1.71) 0.487 0.31
Age 1.02 (0.99-1.06) 0.143 0.01
Time of DM§ 1.04 (1.00-1.08) 0.024 0.01
Home contact hepatitis B 0.97 (0.85-1.10) 0.658 0.06
Work as a police officer 13.82 (1.27-149.94) 0.031 16.81
Sexual partners throughout life 1.00 (0.99-1.00) 0.927 0.001
Alcohol consumption 1.04 (0.75-1.44) 0.806 0.17
Blood/derivative transfusion 0.55 (0.17-1.72) 0.309 0.32
*Those that showed p≤0.20 in the univariate analysis were included. Each variable was adjusted for the other seven; †OR – Odds ratio; ‡CI – Confidence 
interval; §DM – Diabetes mellitus
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Discussion
When comparing the obtained results with the 
population-based survey conducted in Brazil, the 
prevalence of HBV exposure (16.8%) was higher than 
the national prevalence (11.6%) in the general population 
from 20 to 69 years. Regarding the prevalence of acute 
or chronic infection, the prevalence found was lower than 
the national prevalence, with a value of 0.6%(19). This 
result suggests that the prevalence of HBV exposure is 
higher in individuals with DM when compared to those 
without the disease(5).
The prevalence of prior cured infection and vaccine 
immunity marker were higher than in Spain(24). On the 
other hand, studies carried out in Poland and Turkey 
showed two-fold higher values(25-27). Other studies also 
found a higher prevalence(16,25-29).
The association of exposure to HBV and a longer 
time of DM can be interpreted as a cumulative risk of 
exposure to the virus probably attributed to the disease 
management since DM does not progress to hepatitis B or 
C. The association of exposure to HBV and a longer time of 
DM were reported in Poland(26), Turkey(28), and Nigeria(30). 
On the other hand, a study carried out in Italy found no 
association of infection and time of DM(27).
In accordance with another study(27), the present 
study also did not find an association of HBV infection with 
demographic variables, variables related to insulin use, 
monitoring of capillary glycemia, and history of medical, 
surgical, diagnostic, and therapeutic interventions. 
In addition, the majority of the investigated patients 
monitored capillary glycemia at home and outbreaks 
of HBV infection reported in the literature were in 
institutionalized patients and health services undergoing 
assisted monitoring of capillary glycemia without proper 
infection control practices(1-2,4,6).
The prevalence of HCV infection was 3.3% higher 
than the national prevalence for the general population 
from 20 to 69 years old, which was 1.6%(24,27), as well 
as national studies with specific populations such as the 
deaf, military males, and workers collecting household 
waste(31-33). On the other hand, a study that investigated 
the prevalence of HCV infection in elderly patients in 
southern Brazil found a prevalence of 2.2%(34).
The prevalence of hepatitis C in patients investigated 
in our study was also higher than that found in three 
national studies with patients with DM(16-17). The difference 
in the observed prevalence can be attributed to the 
composition of the sample regarding the age group. An 
old age is considered a risk factor for exposure to HCV 
infection(20-21). The time of DM found in these studies was 
also lower than that found in our study, which may also 
justify the difference in the observed prevalence.
On the other hand, a study carried out in southern 
Brazil showed that the prevalence was four times higher 
in patients with DM2 undergoing outpatient care(18). The 
time of DM of the investigated outpatients is higher 
when compared to those of our study, which may have 
contributed to a higher prevalence of infection.
International studies investigating the prevalence 
of HCV exposure in patients with DM in an outpatient 
clinic or hospital found a lower(7,24,30), similar(23,28), and 
higher(8,22,25,27,29) prevalence in relation to our results.
Since the 1990s studies have shown a higher 
prevalence of hepatitis C in patients with DM when 
compared to those without this disease(7-8,16,23,27). When 
comparing the prevalence of hepatitis C in patients with 
DM found in our study (3.3%) and the prevalence observed 
in the general Brazilian population (1.4%)(19), we also 
observed a higher prevalence of infection in patients 
with DM.
However, in our study, although we found a prevalence 
of HCV infection higher than that of the Brazilian population, 
we did not observe an association of HCV infection with 
demographic variables, variables related to insulin use, 
monitoring of capillary glycemia, and history of medical, 
surgical, diagnostic, and therapeutic interventions, which 
is in agreement with national studies(16-18).
Other studies reported in the international literature 
found as variables associated with infection only recognized 
risk factors for hepatitis C such as the history of blood 
transfusion, sharing of sharps, multiple sexual partners, 
and changes in liver enzyme levels(16,18,23,25,29).
A study carried out in France found a significant 
difference in the prevalence of HCV infection in patients 
with (3.1%) and without DM (0.04%). However, the 
hypothesis that the type of treatment for DM, previous 
hospitalizations, and lancet use pen for monitoring the 
capillary glycemia are associated with HCV infection in 
patients with DM has not been confirmed(35).
These results lead to the assumption that HCV 
infection may present as a risk factor for the development 
of DM, as investigated in other studies(36-37). Studies 
have shown that HCV infection is followed by defects 
in the insulin-signaling pathway in the liver, which may 
contribute to insulin resistance and DM(37). However, 
HCV-induced insulin resistance mechanisms are still 
partially understood(14,38). Another study shows that liver 
inflammation is a possible risk factor for pre-diabetes in 
the context of HCV infection(39).
In summary, when considering the higher prevalence 
of HBV exposure and its relation to the time of DM, it is 
suggested to deepen new investigations related to diabetes 
management that may contribute to HBV infection. The 
absence of association of HCV infection with the studied 
variables can be attributed to the relatively low number 
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of infected individuals. This research is a pioneer in Brazil 
and offers subsidies for comparisons with future studies 
and advances in the knowledge of the subject.
This study offers subsidies to know the magnitude 
of the problem and advance the production of knowledge 
about hepatitis B and C and DM. The study can generate 
new research themes, translating into the quality of 
health information and, therefore, qualification of 
nursing care.
Conclusion
The prevalence of HBV infection in patients with DM 
was 16.8%, which is higher than the national level and 
was directly associated with the time of DM. No cases of 
acute or chronic hepatitis B were found. The prevalence 
of HCV infection was 3.3%, which is higher than the 
national level and had no association with the investigated 
demographic and clinical variables. Further studies need 
to be developed to investigate these issues and deepen 
the knowledge of the relationship between hepatitis C 
and DM in the national population aiming at the timely 
adoption of preventive measures.
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